Floatz logo

46 assets in Anal Carcinoma

Therapeutic assets addressing Anal Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Fluorouracilum
Anal Carcinoma
Federation Francophone de Cancerologie DigestiveP3BB (70)
Carboplatin
Anal Carcinoma
Dustin DemingP3BB (68)
Irinotecan
Anal Carcinoma
University of CincinnatiP3BB (67)
Nivolumab
Anal Carcinoma
Instituto do Cancer do Estado de São PauloP3BB (67)
Cis-Diamminedichloroplatinum Ii
Anal Carcinoma
Federation Francophone de Cancerologie DigestiveP3BB (66)
Muamycin
Anal Carcinoma
Federation Francophone de Cancerologie DigestiveP3BB (66)
Cyclophosphamide
Anal Carcinoma
Christian HinrichsP2BB (64)
Oxaliplatin
Anal Carcinoma
University of CincinnatiP2/3B (62)
Capecitabine
Anal Carcinoma
Federation Francophone de Cancerologie DigestiveP3B (60)
Fludarabine
Anal Carcinoma
Christian HinrichsP2B (60)
Fludeoxyglucose
Anal Carcinoma
Jonsson Comprehensive Cancer CenterP2B (60)
9-valent human papillomavirus recombinant vaccine
Anal Carcinoma
Xiamen UniversityP3B (59)
Ipilimumab
Anal Carcinoma
National Cancer Institute (NCI)P2B (59)
Pembrolizumab
Anal Carcinoma
Dustin DemingP2B (59)
pds0101
Anal Carcinoma
Weill Medical College of Cornell UniversityP2B (58)
Atezolizumab
Anal Carcinoma
Oncolytics BiotechP2B (57)
e7 tcr-t cells
Anal Carcinoma
Christian HinrichsP2CCC (55)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap
Anal Carcinoma
National Cancer Institute (NCI)P2CCC (54)
Toripalimab
Anal Carcinoma
Sun Yat-sen UniversityP2CCC (54)
Tislelizumab
Anal Carcinoma
SOLTI Breast Cancer Research GroupP2CCC (53)
Dehydroepiandrosterone
Anal Carcinoma
Ohio State University Comprehensive Cancer CenterP2CCC (52)
Abiraterone
Anal Carcinoma
MacroGenicsP2CCC (51)
Durvalumab
Anal Carcinoma
Goethe UniversityP2CCC (51)
Enzalutamide
Anal Carcinoma
MacroGenicsP2CCC (51)
Retifanlimab
Anal Carcinoma
Jennifer DorthP2CCC (51)
Pelareorep
Anal Carcinoma
Oncolytics BiotechP1/2CCC (48)
Trifluridine/Tipiracil Hydrochloride Combination Agent Tas-102
Anal Carcinoma
Oncolytics BiotechP1/2CCC (48)
Spartalizumab
Anal Carcinoma
SOLTI Breast Cancer Research GroupP2CC (46)
Alpha Tocopherol
Anal Carcinoma
University of NebraskaP1/2CC (43)
coq10
Anal Carcinoma
University of NebraskaP1/2CC (43)
Dexasone
Anal Carcinoma
National Cancer Institute (NCI)P1/2CC (43)
Diphenhydramine
Anal Carcinoma
National Cancer Institute (NCI)P1/2CC (43)
Entinostat
Anal Carcinoma
National Cancer Institute (NCI)P1/2CC (43)
Epinephrine
Anal Carcinoma
National Cancer Institute (NCI)P1/2CC (43)
Hryz-T101 Tcr-T Cell
Anal Carcinoma
HRYZ Biotech Co.P1CC (43)
Ibuprofen
Anal Carcinoma
National Cancer Institute (NCI)P1/2CC (43)
pds01adc
Anal Carcinoma
National Cancer Institute (NCI)P1/2CC (43)
Prgn-2009
Anal Carcinoma
National Cancer Institute (NCI)P1/2CC (43)
ai-061
Anal Carcinoma
OncoC4, Inc.P1C (39)
Crte7A2-01 Tcr-T Cell
Anal Carcinoma
Corregene Biotechnology Co., LtdP1C (39)
Crte7A2-01 Tcr-T Cell Therapy
Anal Carcinoma
Corregene Biotechnology Co., LtdP1C (39)
Hryz-T101
Anal Carcinoma
HRYZ Biotech Co.P1C (39)
kfa115
Anal Carcinoma
Novartis PharmaceuticalsP1C (39)
scg142 tcr-t cells
Anal Carcinoma
The Affiliated Hospital of Qingdao UniversityP1C (39)
Vobramitamab Duocarmazine
Anal Carcinoma
MacroGenicsP2C (36)